Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 240-250

  Capranico, Giovanni ^a   Marinello, Jessica ^a   Baranello, Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Camptothecin; HIF1a; RNA polymerase; Topoisomerase I; Transcription pausing

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; AMINOACRIDINE DERIVATIVE; AROMATHECIN DERIVATIVE; BATRACYLIN; BETA LAPACHONE; BULGAREIN; CALOTHRIXIN DERIVATIVE; CAMPTOTHECIN; CISPLATIN; CORALYNE; DIOSPYRIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; ETOPOSIDE; FAGARONINE; HOE 33342; INDOTECAN; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITIDINE; PLUKENETIONE A; REBECCAMYCIN; SAINTOPIN; STAUROSPORINE; TENIPOSIDE; THASPINE; TOPOPYRONE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMINOACRIDINE; AROMATHECIN; ENZYME INHIBITOR; ERYBRAEDIN C; RNA POLYMERASE II; TAFLUPOSIDE;

ANTINEOPLASTIC ACTIVITY; CHROMATIN STRUCTURE; DNA DAMAGE; DNA REPLICATION; DNA SUPERCOILING; DRUG DNA BINDING; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE LOCUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; DNA STRUCTURE; DRUG MECHANISM;

CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; RNA POLYMERASE II; TOPOISOMERASE I INHIBITORS; TRANSCRIPTION, GENETIC;

EID: 78649491469     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.06.003     Document Type: Review

References (95)

1. Kramer P.R., Sinden R.R. Measurement of unrestrained negative supercoiling and topological domain size in living human cells. Biochemistry 1997, 36:3151-3158.
2. Schvartzman J.B., Stasiak A. A topological view of the replicon. EMBO Rep. 2004, 5:256-261.
3. Hatfield G.W., Benham C.J. DNA topology-mediated control of global gene expression in Escherichia coli. Annu. Rev. Genet. 2002, 36:175-203.
4. Zechiedrich E.L., Khodursky A.B., Bachellier S., Schneider R., Chen D., Lilley D.M., Cozzarelli N.R. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J. Biol. Chem. 2000, 275:8103-8113.
5. Crisona N.J., Strick T.R., Bensimon D., Croquette V., Cozzarelli N.R. Preferential relaxation of positively supercoiled DNA by E. coli topoisomerase IV in single-molecule and ensemble measurements. Genes Dev. 2000, 14:2881-2892.
6. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.
7. Kouzine F., Liu J., Sanford S., Chung H.J., Levens D. The dynamic response of upstream DNA to transcription-generated torsional stress. Nat. Struct. Mol. Biol. 2004, 11:1092-1100.
8. Liu L.F., Wang J.C. Supercoiling of the DNA template during transcription. Proc. Natl Acad. Sci. USA 1987, 84:7024-7027.
9. Kouzine F., Sanford S., Elisha-Feil Z., Levens D. The functional response of upstream DNA to dynamic supercoiling in vivo. Nat. Struct. Mol. Biol. 2008, 15:146-154.
10. Seila A.C., Calabrese J.M., Levine S.S., Yeo G.W., Rahl P.B., Flynn R.A., Young R.A., Sharp P.A. Divergent transcription from active promoters. Science 2008, 322:1849-1851.
11. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400:83-105.
12. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70:369-413.
13. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
14. Khobta A., Ferri F., Lotito L., Montecucco A., Rossi R., Capranico G. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. J. Mol. Biol. 2006, 357:127-138.
15. Merino A., Madden K.R., Lane W.S., Champoux J.J., Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993, 365:227-232.
16. Kretzschmar M., Meisterernst M., Roeder R.G. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Nat. Acad. Sci. U.S.A. 1993, 90:11508-11512.
17. Shykind B.M., Kim J., Stewart L., Champoux J.J., Sharp P.A. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 1997, 11:397-407.
18. Brill S.J., Sternglanz R. Transcription-dependent DNA supercoiling in yeast DNA topoisomerase mutants. Cell 1988, 54:403-411.
19. Tuduri S., Crabbe L., Conti C., Tourriere H., Holtgreve-Grez H., Jauch A., Pantesco V., De V.J., Thomas A., Theillet C., Pommier Y., Tazi J., Coquelle A., Pasero P. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat. Cell Biol. 2009, 11:1315-1324.
20. Miao Z.H., Player A., Shankavaram U., Wang Y.H., Zimonjic D.B., Lorenzi P.L., Liao Z.Y., Liu H., Shimura T., Zhang H.L., Meng L.H., Zhang Y.W., Kawasaki E.S., Popescu N.C., Aladjem M.I., Goldstein D.J., Weinstein J.N., Pommier Y. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 2007, 67:8752-8761.
21. Wall M.E., Wani M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. [Review] [48 refs]. Cancer Res. 1995, 55:753-760.
22. Capranico G., Binaschi M., Borgnetto M.E., Zunino F., Palumbo M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol. Sci. 1997, 18:323-329.
23. Li T.K., Liu L.F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41:53-77.
24. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:15387-15392.
25. Ioanoviciu A., Antony S., Pommier Y., Staker B.L., Stewart L., Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J. Med. Chem. 2005, 48:4803-4814.
26. Marchand C., Antony S., Kohn K.W., Cushman M., Ioanoviciu A., Staker B.L., Burgin A.B., Stewart L., Pommier Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 2006, 5:287-295.
27. Liao Z., Thibaut L., Jobson A., Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol. Pharmacol. 2006, 70:366-372.
28. Miao Z.H., Agama K., Sordet O., Povirk L., Kohn K.W., Pommier Y. Pommier, Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 2006.
29. El-Khamisy S.F., Saifi G.M., Weinfeld M., Johansson F., Helleday T., Lupski J.R., Caldecott K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005, 434:108-113.
30. Cortes L.F., El Khamisy S.F., Zuma M.C., Osborn K., Caldecott K.W. A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009, 461:674-678.
31. Ma M.K., Zamboni W.C., Radomski K.M., Furman W.L., Santana V.M., Houghton P.J., Hanna S.K., Smith A.K., Stewart C.F. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin. Cancer Res. 2000, 6:813-819.
32. Thompson J., Stewart C.F., Houghton P.J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta 1998, 1400:301-319.
33. Covey J.M., Jaxel C., Kohn K.W., Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989, 49:5016-5022.
34. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988, 48:1722-1726.
35. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49:5077-5082.
36. Duann P., Sun M., Lin C.T., Zhang H., Liu L.F. Plasmid linking number change induced by topoisomerase I-mediated DNA damage. Nucleic Acids Res. 1999, 27:2905-2911.
37. Koster D.A., Palle K., Bot E.S., Bjornsti M.A., Dekker N.H. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007, 448:213-217.
38. Uemura T., Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J. 1984, 3:1737-1744.
39. Felsenfeld G., Clark D., Studitsky V. Transcription through nucleosomes. Biophys. Chem. 2000, 86:231-237.
40. Lotito L., Russo A., Chillemi G., Bueno S., Cavalieri D., Capranico G. Global transcription regulation by DNA topoisomerase I in exponentially growing Saccharomyces cerevisiae cells: activation of telomere-proximal genes by TOP1 deletion. J. Mol. Biol. 2008, 377:311-322.
41. Sims R.J., Belotserkovskaya R., Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes Dev. 2004, 18:2437-2468.
42. Darzacq X., Shav-Tal Y., de T., Brody V.Y., Shenoy S.M., Phair R.D., Singer R.H. In vivo dynamics of RNA polymerase II transcription. Nat. Struct. Mol. Biol. 2007, 14:796-806.
43. Wu J., Liu L.F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 1997, 25:4181-4186.
44. Cohen A.A., Geva-Zatorsky N., Eden E., Frenkel-Morgenstern M., Issaeva I., Sigal A., Milo R., Cohen-Saidon C., Liron Y., Kam Z., Cohen L., Danon T., Perzov N., Alon U. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008, 322:1511-1516.
45. Muller M.T., Pfund W.P., Mehta V.B., Trask D.K. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J. 1985, 4:1237-1243.
46. Sordet O., Larochelle S., Nicolas E., Stevens E.V., Zhang C., Shokat K.M., Fisher R.P., Pommier Y. Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J. Mol. Biol. 2008, 381:540-549.
47. Desai S.D., Zhang H., Rodriguez-Bauman A., Yang J.M., Wu X., Gounder M.K., Rubin E.H., Liu L.F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol. 2003, 23:2341-2350.
48. Lotito L., Russo A., Bueno S., Chillemi G., Fogli M.V., Capranico G. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors. Eur. J. Pharmacol. 2009, 603:29-36.
49. Amente S., Gargano B., Napolitano G., Lania L., Majello B. Camptothecin releases P-TEFb from the inactive 7SK snRNP complex. Cell Cycle 2009, 8.
50. Kruhlak M., Crouch E.E., Orlov M., Montano C., Gorski S.A., Nussenzweig A., Misteli T., Phair R.D., Casellas R. The ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks. Nature 2007, 447:730-734.
51. Sordet O., Redon C.E., Guirouilh-Barbat J., Smith S., Solier S., Douarre C., Conti C., Nakamura A.J., Das B.B., Nicolas E., Kohn K.W., Bonner W.M., Pommier Y. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep. 2009, 10:887-893.
52. Baranello L., Bertozzi D., Fogli M.V., Pommier Y., Capranico G. DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus. Nucleic Acids Res. 2010, 38:159-171.
53. Gilchrist D.A., Nechaev S., Lee C., Ghosh S.K., Collins J.B., Li L., Gilmour D.S., Adelman K. NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly. Genes Dev. 2008, 22:1921-1933.
54. Munoz M.J., Perez Santangelo M.S., Paronetto M.P., de la M.M., Pelisch F., Boireau S., Glover-Cutter K., Ben-Dov C., Blaustein M., Lozano J.J., Bird G., Bentley D., Bertrand E., Kornblihtt A.R. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009, 137:708-720.
55. Rossi F., Labourier E., Forne T., Divita G., Derancourt J., Riou J.F., Antoine E., Cathala G., Brunel C., Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996, 381:80-82.
56. Pilch B., Allemand E., Facompre M., Bailly C., Riou J.F., Soret J., Tazi J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 2001, 61:6876-6884.
57. Czubaty A., Girstun A., Kowalska-Loth B., Trzcinska A.M., Purta E., Winczura A., Grajkowski W., Staron K. Proteomic analysis of complexes formed by human topoisomerase I. Biochim. Biophys. Acta 2005, 1749:133-141.
58. Straub T., Knudsen B.R., Boege F. PSF/p54(nrb) stimulates "jumping" of DNA topoisomerase I between separate DNA helices. Biochemistry 2000, 39:7552-7558.
59. Andersen F.F., Tange T.O., Sinnathamby T., Olesen J.R., Andersen K.E., Westergaard O., Kjems J., Knudsen B.R. The RNA splicing factor ASF/SF2 inhibits human topoisomerase I mediated DNA relaxation. J. Mol. Biol. 2002, 322:677-686.
60. Tian B., Yang Q., Mao Z. Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death. Nat. Cell Biol. 2009, 11:211-218.
61. Sakasai R., Teraoka H., Takagi M., Tibbetts R.S. Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison. J. Biol. Chem. 2010, 285:15201-15208.
62. Iyer N.V., Leung S.W., Semenza G.L. The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 1998, 52:159-165.
63. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
64. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 2006, 4:601-605.
65. Lapidot M., Pilpel Y. Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms. EMBO Rep. 2006, 7:1216-1222.
66. Kapranov P., Cheng J., Dike S., Nix D.A., Duttagupta R., Willingham A.T., Stadler P.F., Hertel J., Hackermuller J., Hofacker I.L., Bell I., Cheung E., Drenkow J., Dumais E., Patel S., Helt G., Ganesh M., Ghosh S., Piccolboni A., Sementchenko V., Tammana H., Gingeras T.R. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316:1484-1488.
67. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002, 62:4316-4324.
68. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004, 64:1475-1482.
69. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., Borgel S.D., Carter J.P., Hewitt S.M., Shoemaker R.H., Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004, 64:6845-6848.
70. Jaxel C., Capranico G., Kerrigan D., Kohn K.W., Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991, 266:20418-20423.
71. Verma R.P., Hansch C. Camptothecins: A SAR/QSAR Study (Published on the Web December 19, 2008). Chem. Rev. 2009, 109:1477.
72. Pommier Y., Cushman M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol. Cancer Ther. 2009.
73. Khan Q.A., Elban M.A., Hecht S.M. The topopyrones poison human DNA topoisomerases I and II. J. Am. Chem. Soc. 2008, 130:12888-12889.
74. Khan Q.A., Lu J., Hecht S.M. Calothrixins, a new class of human DNA topoisomerase I poisons. J. Nat. Prod. 2009.
75. Leteurtre F., Fujimori A., Tanizawa A., Chhabra A., Mazumder A., Kohlhagen G., Nakano H., Pommier Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem. 1994, 269:28702-28707.
76. Galvez-Peralta M., Hackbarth J.S., Flatten K.S., Kaufmann S.H., Hiasa H., Xing C., Ferguson D.M. On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorg. Med. Chem. Lett. 2009, 19:4459-4462.
77. Makhey D., Yu C., Liu A., Liu L.F., LaVoie E.J. Substituted benz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Bioorg. Med. Chem. 2000, 8:1171-1182.
78. Gatto B., Sanders M.M., Yu C., Wu H.Y., Makhey D., LaVoie E.J., Liu L.F. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res. 1996, 56:2795-2800.
79. Salas J.A., Mendez C. Indolocarbazole antitumour compounds by combinatorial biosynthesis. Curr. Opin. Chem. Biol. 2009, 13:152-160.
80. Cinelli M.A., Morrell A., Dexheimer T.S., Scher E.S., Pommier Y., Cushman M. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J. Med. Chem. 2008, 51:4609-4619.
81. Cinelli M.A., Cordero B., Dexheimer T.S., Pommier Y., Cushman M. Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg. Med. Chem. 2009, 17:7145-7155.
82. Fujii N., Yamashita Y., Saitoh Y., Nakano H. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J. Biol. Chem. 1993, 268:13160-13165.
83. Facompre M., Tardy C., Bal-Mahieu C., Colson P., Perez C., Manzanares I., Cuevas C., Bailly C. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res. 2003, 63:7392-7399.
84. Borgnetto M.E., Tinelli S., Carminati L., Capranico G. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons. J. Mol. Biol. 1999, 285:545-554.
85. Rao V.A., Agama K., Holbeck S., Pommier Y. Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage. Cancer Res. 2007, 67:9971-9979.
86. Arimondo P.B., Thomas C.J., Oussedik K., Baldeyrou B., Mahieu C., Halby L., Guianvarc'h D., Lansiaux A., Hecht S.M., Bailly C., Giovannangeli C. Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates. Mol. Cell. Biol. 2006, 26:324-333.
87. Li C.J., Averboukh L., Pardee A.B. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. 1993, 268:22463-22468.
88. Khan Q.A., Pilch D.S. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J. Mol. Biol. 2007, 365:561-569.
89. Capranico G., Palumbo M., Tinelli S., Zunino F. Unique sequence specificity of topoisomerase II DNA cleavage stimulation and DNA binding mode of streptonigrin. J. Biol. Chem. 1994, 269:25004-25009.
90. Tazi J., Bakkour N., Soret J., Zekri L., Hazra B., Laine W., Baldeyrou B., Lansiaux A., Bailly C. Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol. Pharmacol. 2005, 67:1186-1194.
91. az-Carballo D., Malak S., Bardenheuer W., Freistuehler M., Peter R.H. The contribution of plukenetione A to the anti-tumoral activity of Cuban propolis. Bioorg. Med. Chem. 2008, 16:9635-9643.
92. Perrin D., van H.B., Barret J.M., Kruczynski A., Etievant C., Imbert T., Hill B.T. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem. Pharmacol. 2000, 59:807-819.
93. Fayad W., Fryknas M., Brnjic S., Olofsson M.H., Larsson R., Linder S. Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. PLoS ONE 2009, 4:e7238.
94. Tesauro C., Fiorani P., D'Annessa I., Chillemi G., Turchi G., Desideri A. Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I. Biochem. J. 2010, 425:531-539.
95. Castelli S., Campagna A., Vassallo O., Tesauro C., Fiorani P., Tagliatesta P., Oteri F., Falconi M., Majumder H.K., Desideri A. Conjugated eicosapentaenoic acid inhibits human topoisomerase IB with a mechanism different from camptothecin. Arch. Biochem. Biophys. 2009, 486:103-110.